Aggregated China Business Blogs



China Aoxing Granted License for Addiction Drug, Still Lacks Firm Financial Footing

Aggregated Source: China Stocks News and Analysis from Seeking Alpha
November 21, 2007|

China Aoxing Pharmaceutical Company (CAXG.OB) received a license from the China State Food & Drug Administration to develop a maintenance treatment for opioid dependence. The treatment, a combination of buprenorphine and naloxone in a sublingual tablet, has been available in the U.S. since 2002.

Original URL: Click here to visit original article
Copyright China Stocks News and Analysis from Seeking Alpha

Print This Post Print This Post | Email This Page Email This Page
No Ratings Yet
Loading ... Loading ...

Related Info:
  • Aoxing Pharmaceutical's Anti-Opioid Addiction Drug Approved by China’s FDA
  • China Aoxing Receives Manufacturing Exclusivity for Cancer Pain Drug
  • License Revoked From Shanghai Hualian Pharmaceutical Factory
  • China Aoxing Pharmaceutical To Acquire Shijiazhuang Company
  • Qualcomm Signs 3G License Agreement With TechFaith

    • No Comments Yet »

    Your comment

    The following HTML tags are permitted:
    <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

    RSS RSS Feed for Comments on this Post |